New Product Launch BIOPONIB®ponatinib

26/04/2023

Bioprofarma Bagó is pleased to present the launch of BIOPONIB® ponatinib for its Hematology Business Unit.

BIOPONIB® ponatinib is approved by ANMAT for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adult patients who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and in whom subsequent treatment with imatinib is not clinically indicated; or who present the T315I mutation.

HOW SUPPLIED:

BIOPONIB® 15 mg x 30 coated tablets
BIOPONIB® 15 mg x 60 coated tablets
BIOPONIB® 45 mg x 60 coated tablets

BIOPONIB® ponatinib joins the portfolio of products for the treatment of CML and ALL PH+, together with CLINID®imatinib and DAPIBUS® dasatinib.

This new treatment alternative comes to provide specialists with more options for the care of their patients.

(Español) Jornada de Uro Oncología FUCDIM

Sorry, this entry is only available in European Spanish.

(Español) Jornada URO ONCOSESSIONS V

Sorry, this entry is only available in European Spanish.

(Español) X Jornadas de actualización en Uro- Oncología del NOA

Sorry, this entry is only available in European Spanish.